{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:10:40Z","timestamp":1761174640508,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,29]],"date-time":"2014-11-29T00:00:00Z","timestamp":1417219200000},"content-version":"vor","delay-in-days":3134,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1111\/j.1469-0691.2006.01372.x","type":"journal-article","created":{"date-parts":[[2006,4,5]],"date-time":"2006-04-05T05:29:10Z","timestamp":1144214950000},"page":"486-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir\u2013ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors"],"prefix":"10.1016","volume":"12","author":[{"given":"P.","family":"Panagopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Antoniadou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Katsarolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Poulakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Giamarellou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2006.01372.x_bib1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1001\/jama.292.2.251","article-title":"Treatment for adult HIV Infection 2004: recommendations of the International AIDS Society\u2010USA Panel","volume":"292","author":"Anonymous","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib2","series-title":"The John Hopkins Hospital 2004\u20132005 guide to medical care of patients with HIV infection","first-page":"49","article-title":"Antiretroviral therapy: management of HIV\u2010infected patients and post\u2010exposure prophylaxis","author":"Bartlett","year":"2004"},{"issue":"suppl","key":"10.1111\/j.1469-0691.2006.01372.x_bib3","first-page":"30","article-title":"Efavirenz: practicalities, considerations and new issues","volume":"103","author":"Moyle","year":"1999","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib4","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa012354","article-title":"Lopinavir\u2013ritonavir versus nelfinavir for the initial treatment of HIV infection","volume":"346","author":"Walmsley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/00002030-200403260-00008","article-title":"Long\u2010term safety and durable antiretroviral activity of lopinavir\/ritonavir in treatment\u2010naive patients: 4 year follow\u2010up study","volume":"18","author":"Hicks","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1097\/00002030-200411190-00017","article-title":"First\u2010line efavirenz versus lopinavir\u2013ritonavir\u2010based highly active antiretroviral therapy for naive patients","volume":"18","author":"Manfredi","year":"2004","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/jac\/dki172","article-title":"Exploratory analysis for the evaluation of lopinavir\/ritonavir versus efavirenz\u2010based HAART regimens in antiretroviral\u2010naive HIV\u2010positive patients: results from the Italian MASTER Cohort","volume":"56","author":"Torti","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib8","first-page":"257","article-title":"Management of metabolic complications associated with antiretroviral therapy for HIV\u20101 infection: recommendations of an International AIDS Society\u2010USA Panel","volume":"31","author":"Schambelan","year":"2002","journal-title":"J AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy antiretroviral\u2010naive patients: a 3\u2010year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib10","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1097\/01.aids.0000176218.40861.14","article-title":"Early virological failure in HIV\u20101 infected subjects on didanosine\/tenofovir\/efavirenz: 12 week results from a randomised trial","volume":"19","author":"Maitland","year":"2005","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib11","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1097\/00002030-200304001-00017","article-title":"HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management","volume":"17","author":"Carr","year":"2003","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib12","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV\u20101\u2010infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long\u2010term nucleoside analogue therapy","volume":"13","author":"Saint\u2010Marc","year":"1999","journal-title":"AIDS"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus\u2010infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1310\/8TXF-P814-8JPF-7TRY","article-title":"Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in the heavily pretreated HIV\u2010infected patients","volume":"4","author":"Clevenbergh","year":"2003","journal-title":"HIV Clin Trials"},{"key":"10.1111\/j.1469-0691.2006.01372.x_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dube","year":"2003","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14620164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14620164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:14:19Z","timestamp":1761117259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14620164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S1198743X14620164"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01372.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir\u2013ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2006.01372.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}